Picture Berlin Partner German Biotech Days 2024 in Berlin 650x100px
Document › Details

Bioharmony Therapeutics, Inc.. (1/15/19). "Press Release: Bioharmony Therapeutics and Boehringer Ingelheim Collaborate to Advance Bacteriophage Lysin Therapeutics for the Treatment of Multi-Drug Resistant Bacterial Infections". New York, NY.

Organisations Organisation Bioharmony Therapeutics Inc.
  Organisation 2 Boehringer Ingelheim (Group)
Products Product bacteriophage therapy
  Product 2 drug discovery
Index term Index term Boehringer–Bioharmony Therapeutics: antibiotics, 201901– collab developm of bateriophage lysins
Persons Person Ghose, Chandrabali (Bioharmony Therapeutics 201901 CEO + Founder)
  Person 2 DeScenza, Lisa (LaVoie Health Science 201901)

> Collaboration aims to develop first-in-class therapies for treatment resistant hospital acquired bacterial infections caused by Acinetobacter baumannii

> Infectious diseases are an area of interest of Boehringer Ingelheim’s Research Beyond Borders (RBB) department, which explores emerging science and technology beyond the company’s core areas of focus

Bioharmony Therapeutics, Inc. (“Bioharmony”), a biopharmaceutical company focusing on the development of novel therapeutics for hard to treat bacterial infections, announced today that it has entered into a Collaborative Research and Licensing Agreement with Boehringer Ingelheim to develop bacteriophage lysins for the treatment of multidrug resistant (MDR) Acinetobacter infections, a frequent cause of hospital-acquired pneumonia and life-threatening blood or wound infections. Bioharmony licensed this technology from the Rockefeller University. The discoveries are from the laboratory of Vincent A. Fischetti, Ph.D., a faculty member at The Rockefeller University. Recently, the World Health Organization listed drug-resistant Acinetobacter baumannii to be a critical priority pathogen, causing around 9% of all bacterial infections in intensive care worldwide against which there are few treatment options available. Financial terms are not disclosed.

Infectious diseases are amongst the leading causes of morbidity and mortality worldwide and continue to be a major health challenge for medicine. Increasing levels of resistance threaten the effectiveness of many existing antimicrobial drugs. Lysins are bacteriophage-derived enzymes that cleave the essential bonds in the bacterial cell wall leading to rapid killing of the target bacteria. As a new antimicrobial class, they could enable the development of urgently needed treatment options for MDR infections.

“We look forward to advancing lysins as a first-in-class antimicrobial for the treatment of multi-drug resistant, bacterial infections,” commented Chandrabali Ghose, Ph.D., founder and CEO of Bioharmony Therapeutics. “Antibiotic resistance is a global health problem with a large unmet medical need due to the evolution of bacteria and its ability to evade the use of antimicrobials. We hope that our novel approach of developing lysins for treating Acinetobacter infections and our partnership with Boehringer Ingelheim will have a positive impact in the fight against antibiotic resistance.”

Jeanne Farrell, Ph.D., Associate Vice President of Technology Advancement at Rockefeller commented, “We are excited about the potential of the Bioharmony program in the fight against multi-drug resistant bacterial infections. This collaboration may lead to new treatments in an area of great unmet need.” Rockefeller has an equity stake in Bioharmony. Rockefeller and Dr. Fischetti may benefit financially as a result of successful commercialization of the licensed technology.

The partnership is part of Boehringer Ingelheim’s Research Beyond Borders function (RBB), which explores emerging science and technology beyond the company’s core areas of focus. RBB also focuses on gene therapy, regenerative medicine, immune-infection, and the role of the microbiome in human health and disease.

About Bioharmony Therapeutics, Inc.

Bioharmony Therapeutics, Inc. is an emerging biopharmaceutical company focused on the discovery and development of first-in-class lysin-based antimicrobial therapeutics for patients with multi-drug resistant Gram-negative bacterial infections. In addition to the Acinetobacter lysin, Bioharmony’s portfolio includes a proprietary line-up of lysins for the treatment for pneumonia, skin, urinary tract and bloodstream infections caused by Gram-negative bacterial infections such as E.coli, Klebsiella and others.

For more information, please visit, contact or follow the company on Twitter at@bioharmonytrx.


Lisa DeScenza
Assistant Vice President, Integrated Communications
(978) 395-5970

Record changed: 2023-06-05


Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top